AstraZeneca PLC (NASDAQ:AZN) went up by 3.31% from its latest closing price compared to the recent 1-year high of $64.94. The company’s stock price has collected 1.55% of gains in the last five trading sessions. Press Release reported on 04/30/21 that FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes
Is It Worth Investing in AstraZeneca PLC (NASDAQ :AZN) Right Now?
AstraZeneca PLC (NASDAQ:AZN) scored a price-to-earnings ratio above its average ratio, recording 43.61 x from its present earnings ratio. Plus, the 36-month beta value for AZN is at 0.56. Opinions of the stock are interesting as 21 analysts out of 26 who provided ratings for AstraZeneca PLC declared the stock was a “buy,” while 2 rated the stock as “overweight,” 2 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $64.72, which is $10.53 above the current price. AZN currently public float of 2.60B and currently shorts hold a 4.13% ratio of that float. Today, the average trading volume of AZN was 10.56M shares.
AZN’s Market Performance
AZN stocks went up by 1.55% for the week, with a monthly jump of 6.74% and a quarterly performance of 4.88%, while its annual performance rate touched 1.51%. The volatility ratio for the week stands at 1.89% while the volatility levels for the past 30 days are set at 1.27% for AstraZeneca PLC. The simple moving average for the period of the last 20 days is 4.43% for AZN stocks with a simple moving average of 0.63% for the last 200 days.
AZN Trading at 6.31% from the 50-Day Moving Average
After a stumble in the market that brought AZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.28% of loss for the given period.
Volatility was left at 1.27%, however, over the last 30 days, the volatility rate increased by 1.89%, as shares surge +7.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.05% upper at present.
During the last 5 trading sessions, AZN rose by +1.55%, which changed the moving average for the period of 200-days by -8.50% in comparison to the 20-day moving average, which settled at $50.99. In addition, AstraZeneca PLC saw 6.16% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for AZN
Current profitability levels for the company are sitting at:
- +16.98 for the present operating margin
- +74.01 for the gross margin
The net margin for AstraZeneca PLC stands at +11.58. The total capital return value is set at 14.29, while invested capital returns managed to touch 10.66. Equity return is now at value 25.10, with 5.20 for asset returns.
Based on AstraZeneca PLC (AZN), the company’s capital structure generated 130.46 points at debt to equity in total, while total debt to capital is 56.61. Total debt to assets is 30.54, with long-term debt to equity ratio resting at 115.18. Finally, the long-term debt to capital ratio is 49.98.
When we switch over and look at the enterprise to sales, we see a ratio of 4.89, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 5.35 and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.96.